| Literature DB >> 30970818 |
Muhammad Rizwan1, Rosiyah Yahya2, Aziz Hassan3, Muhammad Yar4, Ahmad Danial Azzahari5, Vidhya Selvanathan6, Faridah Sonsudin7, Cheyma Naceur Abouloula8.
Abstract
Improving the safety efficacy ratio of existing drugs is a current challenge to be addressed rather than the development of novel drugs which involve much expense and time. The efficacy of drugs is affected by a number of factors such as their low aqueous solubility, unequal absorption along the gastrointestinal (GI) tract, risk of degradation in the acidic milieu of the stomach, low permeation of the drugs in the upper GI tract, systematic side effects, etc. This review aims to enlighten readers on the role of pH sensitive hydrogels in drug delivery, their mechanism of action, swelling, and drug release as a function of pH change along the GI tract. The basis for the selection of materials, their structural features, physical and chemical properties, the presence of ionic pendant groups, and the influence of their pKa and pKb values on the ionization, consequent swelling, and targeted drug release are also highlighted.Entities:
Keywords: biocompatible materials; drug delivery applications; pH sensitive hydrogels; swelling and drug release mechanism
Year: 2017 PMID: 30970818 PMCID: PMC6432076 DOI: 10.3390/polym9040137
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1(a) Hydrogel matrix; (b) physically cross-linked hydrogel matrix; (c) chemically cross-linked hydrogel matrix.
Figure 2Complete classification of hydrogels based on different factors.
Figure 3(a) The four broad areas of smart hydrogels, (b) stimuli sensitive swelling of hydrogels along with their categories, (i) physical stimuli, (ii) chemical stimuli, and (iii) biological stimuli.
Examples of different types of stimuli responsive hydrogels along with their mechanisms in brief
| Nature of Stimulus | Stimulus | Mechanism | Example | Ref. |
|---|---|---|---|---|
| Shift in temperature changes polymer-polymer and polymer-water interaction responsible for swelling and drug release. | Chitosan-Poly(acrylamide) | [ | ||
| Swelling under increased pressure and vice versa. This fact is due to an increase in lower critical solution temperature (LCST) value of hydrogels with pressure. LCST is the temperature below which negative thermoresponsive hydrogels swell. | Poly( | [ | ||
| Exposure to light (UV and visible light) reversibly changes the hydrogel from its flowable form to non-flowable form and vice versa. | Poly(trimethylenium iminium trifluorosulfonimide) and 2,6-bis(benzoxal-2-yl)pyridine blend | [ | ||
| Changes in electrical charge distribution within the hydrogels matrix on the application of electric field cause swelling–deswelling and is consequently responsible for the on demand drug release. | Polythiophene and polypyrrole | [ | ||
| When a magnetic field is applied, it causes pores in the gel to swell leading to drug release. | Magnetite nanoparticles and poly(acrylamide) composite hydrogels | [ | ||
| Exposure to ultrasound temporarily breaks the ionic cross-links in the hydrogels and the drug is released but cross-links are reformed on discontinuation of the ultrasound waves. This facilitates on-demand drug release. | Calcium alginate | [ | ||
| Shift in pH causes change in the charge on the polymer chains leading to swelling and drug release. | Poly(acrylic acid), Guar gum succinate, Kappa-carrageenan/poly(vinyl alcohol) | [ | ||
| Change in ion concentration also causes swelling and drug release. | Kappa carrageenan- | [ | ||
| In CO2 sensors, a pH sensitive hydrogel disc comes in contact with bicarbonate solution. On exposure to CO2, the pH of solution changes resulting in swelling or deswelling of the hydrogel which causes a change in pressure which is a measure of the partial pressure of CO2. | Poly(2-hydroxyethylmethacrylate)- | [ | ||
| Hydrogels show swelling in response to increased glucose concentration. The complex formed between glucose and phenylboronic acid drives the swelling of the hydrogels and consequently insulin release. | Poly(acrylamide)- | [ | ||
| Disulfide linkages in reduction sensitive hydrogels cleave in the reductive environment (high level of glutathione concentration = 0.5–10 mM) in intracellular matrix and release bioactive molecules/drugs. | [poly(ethylene glycol) monomethyl ether]-graft-[disulfide linked poly(amido-amine)] and α-cyclodextrin | [ | ||
| Enzymes cause hydrogel degradation and consequently the drug release. This is called a chemically controlled drug release mechanism. | Glycidylmethacrylate dextran- | [ | ||
| Hydrogels sense the free antigen and undergo swelling followed by drug release. | [ | |||
| Single stranded (ss) DNA grafted hydrogel probes show swelling in the presence of ssDNA. | Single stranded DNA probe- | [ |
Figure 4(a) pH dependent ionization of specific acidic or basic functional groups on hydrogel chains responsible for swelling, (b) pH dependent swelling and drug release mechanism.
Figure 5Structure of (a) chitin, (b) chitosan, (c) glycosaminoglycan, (d) carboxymethyl chitosan, (e) N-succinyl chitosan and (f) guar gum.
Figure 6Structure of guar gum succinate.
Figure 7Structure of (a) Kappa-carrageenan, (b) Iota-Carrageenan, (c) Lambda-carrageenan, (d) dextran.
Figure 8Chemical structure of Xanthan.
Figure 9Structures of (a) cellulose (b) alpha-l-guluronic acid and beta-d-mannuronic acid (the epimers), (c) alginic acid (so called alginate), (d) arrangements of M and G residues as M and G blocks.
Figure 10Structures of (a) poly(acrylic acid), (b) poly(acrylamide), (c) poly(vinyl alcohol), (d) poly(ethylene glycol), (e) poly(vinyl pyrrolidone), (f) poly(lactic acid).
Figure 11Applications of hydrogels in different biomedical fields.
Composition of pH sensitive hydrogels along with the loaded drug and their functions.
| Target | Compositions/Carrier | Drugs | Disease | Ref. | |
|---|---|---|---|---|---|
| Acrylic acid grafted chitosan/poly(vinyl pyrrolidone) cross-linked with glutaraldehyde and | Clarithromycine | Peptic ulcer | [ | ||
| Chitosan cross-linked with citrate or tripolyphosphate | Metronidazole | [ | |||
| Chitosan/poly(vinyl pyrrolidone) blend cross-linked with glutaraldehyde | Amoxicilin | [ | |||
| Hemicellulose | Hemicellulose- | Theophylline | Respiratory tract diseases | [ | |
| Guar gum | Acrylic acid grafted Guar gum blended with β-cyclodextrin and cross-linked with tetraethyl orthosilicate | Dexamethasone | Ulcerative colitis, arthritis. | [ | |
| Cyclodextrin | β-cyclodextrin- | Atorvastatin | Various hyperlipidemias | [ | |
| Poly(ethylene glycol) | Styrene-butadiene-styrene incorporated into methacrylic acid- | Pregabalin | Epilepsy, neuropathic pain, etc. | [ | |
| Poly(vinyl pyrrolidone) | Lignosulfonate grafted poly(acrylic acid)- | Amoxicilin | Bacterial infections | [ | |
| Chitosan | Acrylic acid grafted chitosan | Insulin | Diabetes | [ | |
| Starch | Acrylic acid grafted starch | Rutin | Inflammatory bowel disease, allergy, etc. | [ | |
| Guar gum | Guar gum succinate blended sodium alginate cross-linked with barium ions | Ibuprofen | Anti-inflammatory/anti-analgesic drug | [ | |
| Alginate | Sodium alginate cross-linked with calcium chloride | Hydrocortisone | Allergy, arthritis, asthma. | [ | |
| Gelatin | β-cyclodextrin grafted gelatin cross-linked with oxidized dextrin | 5-Fluorouracil | Cancer | [ | |
| Dextran | Glycidyl methacrylate dextran and poly(acrylic acid) | 5-Aminosalicylic acid | Ulcerative colitis and Crohn’s disease | [ | |
| Chitosan | Chitosan blended with poly(vinyl alcohol) cross-linked with tetraethyl orthosilicate | Dexamethasone | Ulcerative colitis and arthritis | [ | |
Figure 12Drug delivery development from basic research to applications.
pH of different body parts/tissues in human body.
| Fluids Tissue/Cellular Compartment | pH Ranges | References |
|---|---|---|
| Saliva in baccul cavity | 6.7–7.3 | [ |
| Stomach | 2.0 | [ |
| Duodenum | 5.0–8.0 | |
| Jejunum | 6.0–7.0 | [ |
| Ileum | 7.0 | |
| Cecum | 6.4 | [ |
| Colon | 7.0–7.5 | [ |
| Rectum | 7.0 | [ |
| Vagina | 4.0–5.0 | [ |
| Chronic wounds | 5.4–7.4 | [ |
| Extracellular matrix in cancerous tissue | 6.5–7.2 | |
| Lysosomes | 4.5–5.0 | |
| Golgi bodies | 6.4 | |
| Early endosome | 6.0–6.5 | |
| Late endosome | 5.0–6.0 | |
| Blood | 7.35–7.45 | |
| Stratum corneum | 5.0–6.0 | [ |